Company intelligence / Profile preview

Shanghai Jiatan Pharmatech

Shanghai Shi / Shanghai City, China

Ownership: Private
Development stage: Other

Overview

Shanghai Jiatan Pharmatech is a Chinese pharmaceutical company focused on developing small molecule therapeutics for infectious diseases such as tuberculosis and for oncology indications. Its lead TB drug WX‑081 is an oral adenosine triphosphatase inhibitor in Phase II/III trials for pulmonary tuberculosis. The company also has a PI3K-mTOR dual inhibitor (WX390/WXFL10030390) in clinical development for various cancers including STK11-mutant tumors and lymphomas. Early data show promising safety and antitumor activity.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Partnerships

No major global pharma partnerships disclosed; some collaboration with Cisen Pharmaceutical Ltd. as originator or active organization on certain assets.

Beyond the preview

Go deeper on Shanghai Jiatan Pharmatech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jiatan Pharmatech.